MedTrace Logo

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

NCT07764146 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-08-13

No results posted yet for this study

Summary

VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Conditions

  • Alzheimer s Disease

Interventions

DRUG

VY1706 Low dose

Low dose

DRUG

VY1706 Mid dose

Mid Dose

DRUG

VY1706 High Dose

High dose

DEVICE

Anti-AAV9 Total Antibody (TAb) Assay

Anti-AAV9 Total Antibody (TAb) Assay

Sponsors & Collaborators

  • Voyager Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-24
Primary Completion
2029-04-28
Completion
2029-04-28
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07764146 on ClinicalTrials.gov